Hospital
The Miriam Hospital
The Miriam Hospital was paid $138.58M by Medicaid between Jan 2018 and Dec 2024, across 423 billing codes. Its largest line is 99285, emergency room visit (most serious) — 5.1% of everything it billed.
33Billing provider infoTHE MIRIAM HOSPITAL
PROVIDENCE, RI 02906
PROVIDENCE, RI 02906
33aNPI1487649430assigned 09/15/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$138.58M
24GClaims2,151,213
24DCodes billed423
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Rhode Island
Rank by total paid#2 of 11
Median peer was paid$12.56M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MARKELL, PETER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 428,291 | $19.47M | |
| 2019 | 483,839 | $33.41M | |
| 2020 | 195,229 | $14.59M | |
| 2021 | 238,702 | $15.64M | |
| 2022 | 255,531 | $17.46M | |
| 2023 | 321,093 | $21.46M | |
| 2024incomplete | 228,528 | $16.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 11,673 | 9,629 | $7.12M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.7% | 61,049 | 45,579 | $5.15M |
| G0378 | Hospital observation service, per hour | 3.7% | 4,935 | 3,856 | $5.09M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.4% | 56,490 | 41,896 | $4.73M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.1% | 117,616 | 89,766 | $4.33M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.0% | 14,302 | 12,147 | $4.13M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.3% | 41,510 | 31,270 | $3.25M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.3% | 4,846 | 4,233 | $3.15M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 58,286 | 44,941 | $2.58M |
| 80053 | Comprehensive metabolic panel | 1.8% | 68,890 | 54,575 | $2.52M |
| 80061 | Lipid panel | 1.7% | 74,520 | 62,264 | $2.36M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 24,184 | 19,600 | $2.32M |
411 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 35,964 | $2.17M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 16,389 | $1.99M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 14,619 | $1.89M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 53,203 | $1.88M |
| 99283 | Emergency room visit (moderate) | 1.3% | 8,749 | $1.78M |
| 87481 | 1.2% | 8,306 | $1.65M | |
| 82248 | 1.1% | 26,137 | $1.58M | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.1% | 5,452 | $1.52M |
| 84484 | 1.1% | 11,374 | $1.50M | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 3,190 | $1.49M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 5,950 | $1.42M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,575 | $1.36M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 23,488 | $1.35M |
| 82948 | <1% | 6,253 | $1.31M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27,299 | $1.26M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,121 | $1.24M |
| 81514 | <1% | 3,216 | $1.23M | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51,702 | $1.23M |
| 80050 | General health panel | <1% | 22,247 | $1.17M |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,394 | $1.12M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,168 | $1.12M |
| 83690 | <1% | 11,703 | $1.12M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,597 | $1.10M |
| 85027 | <1% | 41,235 | $1.09M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,935 | $1.08M |
| 81001 | <1% | 36,803 | $1.07M | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,955 | $1.01M |
| 83735 | <1% | 18,617 | $997K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 8,133 | $989K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 45,750 | $931K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,538 | $896K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,296 | $872K |
| 87536 | <1% | 5,265 | $872K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,386 | $841K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,974 | $800K |
| 36415 | Collection of venous blood by venipuncture | <1% | 92,378 | $794K |
| 85610 | <1% | 34,942 | $778K | |
| 86803 | <1% | 21,873 | $756K | |
| 86780 | <1% | 24,333 | $751K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,663 | $742K |
| 83013 | <1% | 5,089 | $731K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,994 | $730K |
| 82728 | <1% | 23,961 | $730K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,123 | $719K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,591 | $709K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,878 | $662K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,502 | $651K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,930 | $641K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 9,414 | $620K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,799 | $619K |
| J3490 | Unclassified drugs | <1% | 2,105 | $616K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,668 | $601K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 12,372 | $571K |
| 81003 | <1% | 20,473 | $569K | |
| 82607 | <1% | 16,150 | $558K | |
| 84100 | <1% | 9,976 | $537K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,806 | $512K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,024 | $510K |
| 96376 | <1% | 2,594 | $490K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,429 | $486K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,598 | $485K |
| 84703 | <1% | 5,165 | $481K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,878 | $475K |
| 87088 | <1% | 18,261 | $472K | |
| 87340 | <1% | 16,076 | $461K | |
| 93017 | <1% | 3,191 | $440K | |
| 84403 | <1% | 7,920 | $438K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,929 | $437K |
| 86481 | <1% | 5,254 | $429K | |
| 86140 | <1% | 18,005 | $419K | |
| 85651 | <1% | 21,362 | $399K | |
| 83605 | <1% | 2,611 | $380K | |
| 87522 | Neg quan hep c or qual rna | <1% | 4,247 | $379K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,478 | $374K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,232 | $367K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,522 | $367K |
| 86003 | <1% | 2,262 | $350K | |
| 85730 | <1% | 4,651 | $350K | |
| 84439 | <1% | 15,527 | $344K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,931 | $334K |
| 84153 | <1% | 8,153 | $327K | |
| 87186 | <1% | 12,261 | $327K | |
| 86900 | <1% | 4,457 | $325K | |
| 83880 | <1% | 4,065 | $323K | |
| 86850 | <1% | 4,309 | $321K | |
| 86706 | <1% | 10,746 | $316K | |
| 87507 | <1% | 500 | $315K | |
| 86901 | <1% | 4,455 | $312K | |
| 86618 | <1% | 7,041 | $305K | |
| 83540 | <1% | 17,667 | $286K | |
| 84460 | <1% | 20,213 | $270K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 823 | $267K |
| 86360 | <1% | 2,936 | $258K | |
| 84450 | <1% | 19,427 | $257K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,742 | $255K |
| 85379 | <1% | 2,983 | $247K | |
| 80076 | <1% | 15,410 | $246K | |
| 83550 | <1% | 11,483 | $241K | |
| 87529 | <1% | 1,990 | $241K | |
| 85007 | <1% | 6,611 | $234K | |
| 83970 | <1% | 3,466 | $233K | |
| 87077 | <1% | 10,253 | $232K | |
| 82565 | <1% | 18,923 | $227K | |
| 83655 | <1% | 17,067 | $224K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,425 | $223K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,001 | $218K |
| 86704 | <1% | 6,270 | $212K | |
| 82805 | <1% | 1,527 | $212K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,015 | $203K |
| 82670 | <1% | 3,310 | $202K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,620 | $202K |
| 86038 | <1% | 7,093 | $197K | |
| 87510 | <1% | 4,692 | $196K | |
| 87480 | <1% | 4,688 | $196K | |
| 97161 | <1% | 1,809 | $193K | |
| 86762 | <1% | 5,097 | $193K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,298 | $192K |
| 84702 | <1% | 4,527 | $188K | |
| 93797 | <1% | 2,359 | $187K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 881 | $185K |
| 87070 | <1% | 6,881 | $185K | |
| 80074 | <1% | 1,944 | $182K | |
| 82550 | <1% | 6,203 | $181K | |
| 93350 | <1% | 742 | $178K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,264 | $177K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 759 | $175K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,199 | $172K |
| 86787 | <1% | 4,970 | $170K | |
| 86359 | <1% | 2,922 | $166K | |
| 81025 | <1% | 2,403 | $166K | |
| 82746 | <1% | 6,055 | $166K | |
| 84270 | <1% | 3,685 | $165K | |
| 82043 | <1% | 12,751 | $163K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 758 | $163K |
| 83001 | <1% | 3,828 | $161K | |
| 87660 | <1% | 4,678 | $159K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 891 | $158K |
| 88304 | <1% | 734 | $154K | |
| 86235 | <1% | 2,086 | $147K | |
| 84146 | <1% | 3,394 | $145K | |
| C1769 | Guide wire | <1% | 494 | $141K |
| 87081 | <1% | 1,257 | $138K | |
| 82652 | <1% | 1,674 | $136K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 934 | $130K |
| 83516 | <1% | 3,810 | $129K | |
| 84520 | <1% | 12,163 | $125K | |
| 86617 | <1% | 1,745 | $124K | |
| 82784 | <1% | 4,646 | $123K | |
| 87205 | <1% | 5,161 | $123K | |
| 97803 | <1% | 2,271 | $122K | |
| 83002 | <1% | 2,898 | $121K | |
| 97162 | <1% | 1,100 | $121K | |
| 86665 | <1% | 1,448 | $121K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 875 | $118K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 377 | $117K |
| 84480 | <1% | 3,424 | $115K | |
| 93798 | <1% | 1,450 | $114K | |
| 80051 | <1% | 8,422 | $113K | |
| 87505 | <1% | 544 | $110K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 501 | $109K |
| 97804 | <1% | 1,090 | $105K | |
| 86160 | <1% | 2,069 | $104K | |
| 73560 | <1% | 805 | $104K | |
| 86708 | <1% | 2,771 | $100K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,518 | $98K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,317 | $97K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 596 | $96K |
| 87040 | <1% | 745 | $96K | |
| 87902 | <1% | 263 | $95K | |
| 83721 | <1% | 4,106 | $94K | |
| 84550 | <1% | 5,309 | $94K | |
| 87147 | <1% | 2,165 | $92K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 371 | $91K |
| 71250 | <1% | 396 | $91K | |
| 85014 | <1% | 4,707 | $90K | |
| 85018 | <1% | 4,726 | $90K | |
| 83020 | <1% | 2,370 | $88K | |
| 93975 | <1% | 332 | $82K | |
| 82570 | <1% | 5,369 | $81K | |
| 82947 | <1% | 7,914 | $81K | |
| 86735 | <1% | 2,557 | $78K | |
| 86765 | <1% | 2,611 | $78K | |
| J1815 | Injection, insulin, per 5 units | <1% | 148 | $77K |
| 99153 | Mod sedat endo service >5yrs | <1% | 397 | $76K |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 2,628 | $75K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 415 | $75K |
| 86696 | <1% | 1,401 | $74K | |
| 84425 | <1% | 3,280 | $73K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 401 | $73K |
| 82310 | <1% | 4,312 | $72K | |
| 86039 | <1% | 2,822 | $71K | |
| 86431 | <1% | 4,660 | $71K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 370 | $70K |
| 84134 | <1% | 2,140 | $70K | |
| 96367 | <1% | 128 | $68K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 338 | $67K |
| 82040 | <1% | 6,138 | $67K | |
| 87650 | <1% | 1,687 | $66K | |
| 80164 | <1% | 1,962 | $66K | |
| 86480 | <1% | 1,172 | $65K | |
| 86225 | <1% | 2,035 | $64K | |
| 99152 | <1% | 341 | $64K | |
| 84481 | <1% | 3,306 | $63K | |
| 88342 | <1% | 392 | $63K | |
| 93971 | <1% | 805 | $61K | |
| 86200 | <1% | 2,374 | $61K | |
| 86695 | <1% | 1,248 | $59K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 447 | $56K |
| 86592 | <1% | 2,892 | $56K | |
| 87641 | <1% | 1,154 | $56K | |
| 87640 | <1% | 1,144 | $56K | |
| 82140 | <1% | 1,242 | $54K | |
| 83615 | <1% | 2,719 | $54K | |
| 93296 | <1% | 741 | $54K | |
| 86664 | <1% | 1,398 | $54K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 337 | $53K |
| 84466 | <1% | 1,818 | $52K | |
| S9433 | Medical food nutritionally complete, administered orally, providing 100% of nutritional intake | <1% | 863 | $52K |
| 70498 | <1% | 179 | $51K | |
| 82105 | <1% | 1,339 | $49K | |
| 70496 | <1% | 164 | $48K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 93 | $48K |
| 86663 | <1% | 1,398 | $47K | |
| 82627 | <1% | 950 | $47K | |
| 82150 | <1% | 2,819 | $47K | |
| 86376 | <1% | 1,340 | $47K | |
| 83993 | <1% | 1,247 | $45K | |
| 86364 | <1% | 2,198 | $44K | |
| 82465 | <1% | 3,865 | $44K | |
| 77080 | <1% | 475 | $43K | |
| 73630 | <1% | 358 | $43K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 102 | $43K |
| 84156 | <1% | 4,055 | $42K | |
| 82533 | <1% | 1,024 | $42K | |
| 87653 | <1% | 615 | $40K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 20 | $40K |
| 88141 | <1% | 1,431 | $39K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,001 | $39K |
| 84207 | <1% | 619 | $38K | |
| 85060 | <1% | 1,658 | $38K | |
| 84402 | <1% | 646 | $38K | |
| 83718 | <1% | 2,050 | $37K | |
| 84075 | <1% | 2,463 | $36K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 545 | $36K |
| 80197 | <1% | 2,480 | $36K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 609 | $35K |
| 83525 | <1% | 1,311 | $34K | |
| 86308 | <1% | 1,243 | $33K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 153 | $32K |
| 82950 | <1% | 2,609 | $31K | |
| 93225 | <1% | 356 | $31K | |
| 86800 | <1% | 861 | $31K | |
| 73030 | <1% | 409 | $30K | |
| 82977 | <1% | 1,829 | $30K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 75 | $30K |
| 84436 | <1% | 1,916 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 194 | $29K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 249 | $29K |
| 88112 | <1% | 245 | $29K | |
| 85045 | <1% | 2,026 | $27K | |
| 82247 | <1% | 2,208 | $27K | |
| 84132 | <1% | 2,361 | $26K | |
| 73130 | <1% | 243 | $26K | |
| 86705 | <1% | 805 | $26K | |
| 87015 | <1% | 494 | $26K | |
| 73610 | <1% | 189 | $25K | |
| 82785 | <1% | 519 | $25K | |
| 76813 | <1% | 194 | $24K | |
| 87517 | <1% | 278 | $23K | |
| 84155 | <1% | 1,709 | $23K | |
| 80069 | <1% | 2,048 | $23K | |
| 88341 | <1% | 106 | $22K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $22K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 62 | $22K |
| 80178 | <1% | 1,322 | $22K | |
| 97166 | <1% | 119 | $21K | |
| 87338 | <1% | 825 | $21K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 45 | $21K |
| 84165 | <1% | 915 | $21K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 474 | $20K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,375 | $19K |
| 86666 | <1% | 335 | $19K | |
| 84478 | <1% | 1,184 | $19K | |
| 84295 | <1% | 799 | $18K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 270 | $18K |
| 83520 | <1% | 550 | $17K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 121 | $17K |
| 86147 | <1% | 126 | $16K | |
| 86753 | <1% | 353 | $16K | |
| 97802 | <1% | 134 | $16K | |
| 93299 | <1% | 261 | $15K | |
| 72100 | <1% | 124 | $14K | |
| 86593 | <1% | 569 | $14K | |
| G0424 | Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day | <1% | 399 | $14K |
| 76830 | Ultrasound, transvaginal | <1% | 83 | $14K |
| 86256 | <1% | 538 | $13K | |
| 83498 | <1% | 219 | $13K | |
| 87901 | <1% | 33 | $13K | |
| 82747 | <1% | 298 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 298 | $12K |
| 99412 | <1% | 340 | $12K | |
| 93246 | <1% | 238 | $12K | |
| 73502 | <1% | 214 | $11K | |
| 84300 | <1% | 304 | $10K | |
| 87184 | <1% | 352 | $10K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 63 | $10K |
| 87493 | <1% | 166 | $9K | |
| 84590 | <1% | 298 | $9K | |
| 94060 | <1% | 72 | $8K | |
| 97165 | <1% | 38 | $8K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 86 | $8K |
| 87799 | <1% | 148 | $8K | |
| 73590 | <1% | 50 | $8K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 26 | $8K |
| 86709 | <1% | 262 | $8K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 21 | $8K |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 1,244 | $7K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 39 | $7K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 70 | $7K |
| 83921 | <1% | 257 | $7K | |
| 86141 | <1% | 303 | $7K | |
| G0008 | Administration of influenza virus vaccine | <1% | 191 | $7K |
| 84305 | <1% | 153 | $6K | |
| 86258 | <1% | 148 | $6K | |
| 87207 | <1% | 246 | $6K | |
| 86146 | <1% | 62 | $6K | |
| ATP08 | <1% | 1,991 | $6K | |
| 87625 | <1% | 89 | $6K | |
| 84252 | <1% | 110 | $6K | |
| 93298 | <1% | 69 | $6K | |
| 82274 | <1% | 223 | $6K | |
| 93325 | <1% | 28 | $5K | |
| 84630 | <1% | 168 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 44 | $5K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 26 | $5K |
| 82951 | <1% | 151 | $4K | |
| 82330 | <1% | 197 | $4K | |
| 86677 | <1% | 144 | $4K | |
| 94729 | <1% | 64 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 27 | $4K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 86 | $4K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 81 | $4K |
| 83090 | <1% | 128 | $4K | |
| 94727 | <1% | 55 | $4K | |
| 87140 | <1% | 232 | $3K | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 49 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 162 | $3K |
| 74246 | <1% | 32 | $3K | |
| 86255 | <1% | 124 | $3K | |
| 0002A | <1% | 95 | $3K | |
| 82525 | <1% | 98 | $3K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 17 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 34 | $3K |
| 90715 | <1% | 29 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 24 | $3K |
| 0001A | <1% | 109 | $2K | |
| 86231 | <1% | 104 | $2K | |
| 84154 | <1% | 22 | $2K | |
| 93280 | <1% | 173 | $2K | |
| 93320 | <1% | 12 | $2K | |
| 80177 | <1% | 67 | $2K | |
| 72170 | <1% | 16 | $2K | |
| 82374 | <1% | 15 | $2K | |
| 73110 | <1% | 34 | $2K | |
| 93270 | <1% | 14 | $1K | |
| 87430 | <1% | 62 | $1K | |
| 82952 | <1% | 151 | $1K | |
| 83519 | <1% | 43 | $1K | |
| 90662 | <1% | 55 | $1K | |
| 86694 | <1% | 38 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 14 | $1K |
| G0239 | Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring) | <1% | 65 | $1K |
| 86334 | <1% | 41 | $1K | |
| 82010 | <1% | 22 | $1K | |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | <1% | 21 | $950.68 |
| 93880 | <1% | 13 | $846.54 | |
| 85612 | <1% | 26 | $809.73 | |
| 85613 | <1% | 26 | $803.14 | |
| 86769 | <1% | 12 | $796.65 | |
| 86355 | <1% | 14 | $726.67 | |
| 86357 | <1% | 14 | $725.47 | |
| 93290 | <1% | 17 | $723.03 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 29 | $711.64 |
| 99201 | <1% | 12 | $660.36 | |
| 0012A | <1% | 17 | $590.75 | |
| 87206 | <1% | 62 | $588.77 | |
| 82340 | <1% | 39 | $576.88 | |
| 84133 | <1% | 28 | $570.82 | |
| 80305 | <1% | 30 | $549.92 | |
| 86328 | <1% | 12 | $501.21 | |
| 82435 | <1% | 40 | $486.49 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 67 | $472.88 |
| ATP15 | <1% | 55 | $447.54 | |
| 86381 | <1% | 13 | $444.05 | |
| 87075 | <1% | 21 | $429.22 | |
| 85240 | <1% | 12 | $427.36 | |
| 82103 | <1% | 13 | $426.22 | |
| 74018 | <1% | 15 | $409.70 | |
| 82397 | <1% | 13 | $397.75 | |
| 83695 | <1% | 12 | $347.35 | |
| 0011A | <1% | 17 | $341.36 | |
| 82390 | <1% | 13 | $339.55 | |
| 82180 | <1% | 13 | $306.78 | |
| 86036 | <1% | 16 | $299.78 | |
| 93282 | <1% | 12 | $296.39 | |
| 87102 | <1% | 18 | $172.20 | |
| 82436 | <1% | 14 | $140.61 | |
| ATP14 | <1% | 78 | $120.93 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 139 | $37.28 |
| ATP10 | <1% | 27 | $17.92 | |
| 0250 | 0% | 1,844 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARKELL, PETER (E VP & CFO)
Parent organizationLIFESPAN CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Rhode Island Hospital | Providence, RI | $380.77M |
| Gateway Healthcare INC | Pawtucket, RI | $122.93M |
| Emma Pendleton Bradley Hospital | Riverside, RI | $37.64M |
| Newport Hospital | Newport, RI | $15.82M |
| Rhode Island Hospital | Providence, RI | $13.22M |
| Lifespan Physician Group, INC. | Warwick, RI | $6.48M |
| Lifespan Physician Group, INC. | Providence, RI | $5.64M |
| Rhode Island Hospital | Providence, RI | $5.32M |
| Emma Pendleton Bradley Hospital | East Providence, RI | $5.03M |
| Lifespan Physician Group INC | Providence, RI | $4.41M |
| Rhode Island Hospital | Providence, RI | $3.97M |
| Newport Hospital | Newport, RI | $3.05M |
| Rhode Island Hospital | East Providence, RI | $2.58M |
| Vna Technicare, INC. | Providence, RI | $2.52M |
| Rhode Island Hospital | Providence, RI | $2.33M |
| Coastal Medical Physicians, INC. | Providence, RI | $1.33M |
| Gateway Healthcare, INC. | Pawtucket, RI | $1.31M |
| Coastal Medical Physicians, INC. | Providence, RI | $1.20M |
| Gateway Healthcare, INC | Johnston, RI | $1.13M |
| Gateway Healthcare, INC | Charlestown, RI | $731K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.